Literature DB >> 30204220

Transcatheter closure of the patent ductus arteriosus at a public sector hospital in Soweto, South Africa: a review of patient outcomes over 15 years.

Paul Ernest Adams1, Matthew Francis Chersich2, Antoinette Cilliers3.   

Abstract

BACKGROUND: Methods of closing patent ductus arteriosus (PDA) have evolved over time. We review this development in our setting.
METHODS: This was a retrospective analysis of children who had transcatheter PDA closure at Chris Hani Baragwanath Hospital between 1993 and 2008.
RESULTS: Over 15 years, 1 254 PDAs were diagnosed, of which 293 required intervention; 139 patients had transcatheter closure, the median age was 1.8 years (interquartile range = 1-4.5 years) and 66% were female (92/139). Mean PDA diameter was 3.2 mm (standard deviation = 1.6 mm), with an average 2:1 shunt. Transcatheter closure was performed using COOK® Flipper coils (n = 93) or Amplatzer™ devices (n = 46). Early occlusion rates for coils were 52% (39/75) and late occlusion occurred in 91% (68/75) of patients. For Amplatzer devices, early occlusion rates were 94% (33/35) and late occlusion was 100%. Amplatzer™ devices, available since 2003, were overwhelmingly used in the later years.
CONCLUSIONS: Transcatheter PDA closure was safe and effective in this setting, with outcomes similar to reports elsewhere.

Entities:  

Keywords:  intervention; percutaneous; transcatheter; patent ductus arteriosus (PDA)

Mesh:

Year:  2018        PMID: 30204220     DOI: 10.5830/CVJA-2018-028

Source DB:  PubMed          Journal:  Cardiovasc J Afr        ISSN: 1015-9657            Impact factor:   1.167


  1 in total

Review 1.  Impacts of High Environmental Temperatures on Congenital Anomalies: A Systematic Review.

Authors:  Marjan Mosalman Haghighi; Caradee Yael Wright; Julian Ayer; Michael F Urban; Minh Duc Pham; Melanie Boeckmann; Ashtyn Areal; Bianca Wernecke; Callum P Swift; Matthew Robinson; Robyn S Hetem; Matthew F Chersich
Journal:  Int J Environ Res Public Health       Date:  2021-05-05       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.